代偿期乙肝肝硬化通过恩替卡韦联合替比夫定治疗 的疗效分析
陈保生
（北京大学首钢医院，北京，100144）
中图分类号：R256.42 文献标识码：A 文章编号：1674-7860（2016）15-0076-03 证型：IDGB
【摘 要】目的：探讨代偿期乙肝肝硬化通过恩替卡韦联合替比夫定治疗的疗效。方法：研究我院2014年6月—2015年12月收治的80例代偿期乙肝肝硬化患者，分为对照组和观察组各40例，其中对照组运用常规治疗，观察组运用恩替卡韦联合替比夫定治疗，分析两组患者治疗效果差异。结果：在治疗4～48周，观察组HBV-DNA转阴率显著高于对照组，两组差异具有统计学意义，P＜0.05；在治疗后肝功能、Child-Pugh评分和纤维化指标上，观察组改善幅度要高于对照组，两组差异具有统计学意义，P＜0.05；治疗前后A/G、HA、LN、PC-Ⅲ、Ⅳ-C上，观察组改善幅度均高于对照组，两组差异具有统计学意义，P＜0.05；在治疗总有效率上，观察组为95.0%，对照组为82.5%，两组差异具有统计学意义，P＜0.05。结论：代偿期乙肝肝硬化通过恩替卡韦联合替比夫定治疗可以有效提升治疗疗效，改善各相关功能指标，适用于临床广泛推广。
【关键词】代偿期乙肝肝硬化；恩替卡韦；替比夫定；治疗效果
【Abstract】Objective: To investigate the therapeutic effect of entecavircombined with telbivudine in treating Hepatitis B cirrhosis incompensatory stage. Methods:80patients with Hepatitis B cirrhosis in compensatory stage, admitted to ourhospital from June 2014 to December 2015, were divided into the control groupand the observation group, with 40 cases in each group, the control groupreceived conventional treatment while the observation group received entecavircombined with telbivudine, the different effects of two groups of patients wereanalyzed. Results:During4 to 48 weeks of treatment, HBV-DNA negative rate of the observation group wassignificantly better than that of the control group, the difference wasstatistically significant, P<0.05; the improvement of the liver functionafter treatment, Child-Pugh score and fibrosis markers of the observation groupwas significantly better than that of the control group, the difference wasstatistically significant, P＜0.05; the improvement of A/G, HA, LN, PC-Ⅲ and Ⅳ-C, bothbefore and after treatment, of the observation group was significantly betterthan that of the control group, the difference was statistically significant, P＜0.05; The effective rate of the observation group was 95.0%and that of the control group was 82.5%, the difference was statisticallysignificant, P＜0.05. Conclusion:Entecavir combined with telbivudine could improve the therapeuticeffect effectively in treating Hepatitis B cirrhosis in compensatory stageand improve the related functional indexes; therefore, it was applicable inwide clinical promotion.
【Keywords】Hepatitis Bcirrhosis in compensatory stage; Entecavir; Telbivudine; Therapeutic effect
doi:10.3969/j.issn.1674-7860.2016.15.037
参考文献：
[1]刘汶,王俊丽,戚团结,等.穴位贴敷配合清化解毒方治疗乙型肝炎湿热证的临床研究[J].北京中医药,2011,30(10):726-730.
[2]陈晓明,张懿德,刘小莲,等.谢晶日教授从伏气辨治慢性乙型病毒性肝炎经验[J].中国医药导报,2010,07(22):133-134.
[3]Ji-li Yuan, Hua Zhang, LeiWang, et al. Biochemical characteristics of traditional Chinese medicinesyndromes and their elements in patients with hepatitis B cirrhosis[J].Journal of Chinese Integrative Medicine, 2011, 9(4):374-381.
[4]谭善忠,谢碧红,常家宝,等.中药高位保留灌肠联合西药治疗慢性乙型肝炎肝功能衰竭湿热发黄证患者近期疗效[J].中医杂志,2011,52(13):1119-1121.
[5]张少麟.中医药清热利湿法验方治疗乙型病毒性肝炎1例[J].实用医药杂志,2012,29(6):524-524.
[6]Qing-bo Lang, Chang-xia Zhai,Feng Huang, et al.Investigation on traditional Chinese medicine syndrome distributionof 4 618 hepatitis B virus infection subjects in Qidong of Jiangsu Province,China[J]. Journal of Chinese Integrative Medicine,2012,10(5): 525-531.
[7]张磊,周雪忠,于剑,等.592例慢性乙型病毒性肝炎湿热证有效病例用药规律研究[J].中医杂志,2013,54(8):668-672.
[8]龙欢,李平.清热祛湿活血方治疗慢性乙型病毒性肝炎临床观察[J].湖北中医杂志,2009,31(3):32-33.
[9]管艳,张辉,张玮,等.慢性乙型病毒性肝炎肝肾阴虚证与湿热蕴结证患者外周血的差异基因表达谱分析[J].中西医结合学报,2012,10(7):751-756.
基金项目：
广东省中医药局建设中医药强省课题（项目编号20111095）。
作者简介：
陈佩婵（1981-），广东肇庆人，女，毕业于南方医科大学，硕士研究生，主治医师，中西医结合消化内科、肝胆疾病的临床诊治。
 |
